Cephalon Submits New Drug Application For TREANDA For The Treatment Of Chronic Lymphocytic Leukemia
Cephalon, Inc. (Nasdaq: CEPH) announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) requesting approval of TREANDA(R) (bendamustine HCl) for the treatment of patients with chronic lymphocytic leukemia (CLL). CLL is a slowly progressing blood and bone marrow disease with an estimated 15,000 new cases diagnosed every year in the United States, according to the National Cancer Institute.
